This trial is active, not recruiting.

Conditions retinal detachment, vitreoretinopathy proliferative
Treatment bevacizumab
Target VEGF
Sponsor Wills Eye
Start date June 2013
End date November 2014
Trial size 20 participants
Trial identifier NCT01860586, HsuPVR13, MARPVR2013


The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
bevacizumab Avastin
.005 mL of Bevacizumab will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.

Primary Outcomes

The effect of intravitreal bevacizumab injections on retinal detachment rate (increase or decrease)
time frame: up to 6 months

Secondary Outcomes

The effect of intravitreal bevacizumab injections on the development of recurrent Proliferative vitreoretinopathy (PVR).
time frame: 6 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Ability to provide written informed consent and comply with study assessments for the full duration of the study - Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation. Exclusion Criteria: - Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery. - Traction retinal detachment due to proliferative diabetic retinopathy. - Inability to flatten retina completely intraoperatively - Known allergy or contraindication to intravitreal bevacizumab

Additional Information

Official title A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy
Principal investigator Jason Hsu, MD
Trial information was received from ClinicalTrials.gov and was last updated in September 2014.
Information provided to ClinicalTrials.gov by Wills Eye.